Oxidative stress, as one of the pathophysiological mechanisms involved in the reduction of myocardial contractility, stimulates the proliferation of cardiac fibroblasts and the activation of matrix metalloproteinases, which leads to extracellular matrix remodeling. Left ventricular hypertrophy (LVH) is a well-known independent risk factor for cardiovascular events. The aim of this research was to determine the connection between the parameters of oxidative stress and left ventricular geometry indicators in patients with chronic heart failure. The study included 81 subjects diagnosed with heart failure and 68 subjects in the control group. Parameters of myocardial morphology and left ventricular function were measured by echocardiography. Thiobarbituric acid reactive substances (TBARS) content, advanced oxidation protein products (AOPP), total serum SH groups and catalase activity were performed in both groups. The results showed that there were significantly higher concentrations of TBARS, AOPP, and SH groups in patients compared to controls (p < 0.01) and higher concentration of TBARS in patients with concentric hypertrophy compared to patients with normal geometry (p < 0.05). Correlation analysis showed a strong positive correlation between geometry parameters and myocardial function and TBARS and negative correlation between the right ventricule diameter and catalase activity. The results of this study show that oxidative stress parameters are significantly elevated in patients with heart failure, and that concentrations of TBARS and AOPP - the markers of lipid and protein oxidation, strongly correlate with left ventricular geometry parameters.
References
1.
Radovanovic S, Savic-Radojevic A, Pljesa-Ercegovac M, Djukic T, Suvakov S, Krotin M, et al. Markers of Oxidative Damage and Antioxidant Enzyme Activities as Predictors of Morbidity and Mortality in Patients With Chronic Heart Failure. Journal of Cardiac Failure. 2012;18(6):493–501.
2.
Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Heart. 1991;65(5):245–8.
3.
Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, et al. Direct Evidence for Increased Hydroxyl Radicals Originating From Superoxide in the Failing Myocardium. Circulation Research. 2000;86(2):152–7.
4.
Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and Atherosclerosis. Cardiovascular Drugs and Therapy. 2011;25(5):419–29.
5.
Sugimoto K, Ishibashi T, Sawamura T, Inoue N, Kamioka M, Uekita H, et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovascular Research. 2009;84(1):127–36.
6.
Koba S, Gao Z, Sinoway LI. Oxidative stress and the muscle reflex in heart failure. The Journal of Physiology. 2009;587(21):5227–37.
7.
ZHOU Q, WU S, JIANG J, TIAN J, CHEN J, YU X, et al. Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients. Nephrology. 2012;17(7):642–9.
8.
Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, et al. Advanced Oxidation Protein Products Accelerate Atherosclerosis Through Promoting Oxidative Stress and Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(5):1156–62.
9.
Radovanovic S, Krotin M, Simic DV, Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M, et al. Markers of oxidative damage in chronic heart failure: role in disease progression. Redox Report. 2008;13(3):109–16.
10.
McMURRAY J, CHOPRA M, ABDULLAH I, SMITH WE, DARGIE HJ. Evidence of oxidative stress in chronic heart failure in humans. European Heart Journal. 1993;14(11):1493–8.
11.
Díaz-Vélez CR, García-Castiñeiras S, Mendoza-Ramos E, Hernández-López E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. American Heart Journal. 1996;131(1):146–52.
12.
Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, et al. Oxidative Stress–Mediated Cardiac Cell Death Is a Major Determinant of Ventricular Dysfunction and Failure in Dog Dilated Cardiomyopathy. Circulation Research. 2001;89(3):279–86.
13.
Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. Molecular and Cellular Biochemistry. 1995;147(1–2):77–81.
14.
Amir O, Paz H, Rogowski O, Barshai M, Sagiv M, Shnizer S, et al. Serum Oxidative Stress Level Correlates with Clinical Parameters in Chronic Systolic Heart Failure Patients. Clinical Cardiology. 2009;32(4):199–203.
15.
Karabacak M, Dogan A, Tayyar S, Bas HA. Oxidative Stress Status Increase in Patients with Nonischemic Heart Failure. Medical Principles and Practice. 2014;23(6):532–7.
16.
Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. American Heart Journal. 2006;152(1):94–101.
17.
Szczurek W, Szyguła-Jurkiewicz B. EXPERIMENTAL CARDIOVASCULAR AND LUNG RESEARCH Oxidative stress and inflammatory markers – the future of heart failure diagnostics? Polish Journal of Cardio-Thoracic Surgery. 2015;2:145–9.
18.
Andreeva IL, Kožemjakin AL, Kiškun AA. Modification of the method of measurement of lipid peroxides in test with thiobarbituric acid. Lab Delo. 1988:41–3.
19.
Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. American Journal of Physiology-Heart and Circulatory Physiology. 2011;301(6):H2181–90.
20.
Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased Oxidative Stress in Patients With Congestive Heart Failure 11This study was supported by a grant jointly sponsored by the Medical Research Council of Canada, Ottawa and Bayer Pharmaceuticals, Etobicoke, Ontario, Canada. Journal of the American College of Cardiology. 1998;31(6):1352–6.
21.
Nishiyama Y, Ikeda H, Haramaki N, Yoshida N, Imaizumi T. Oxidative stress is related to exercise intolerance in patients with heart failure. American Heart Journal. 1998;135(1):115–20.
22.
Gao WD, Liu Y, Marban E. Selective Effects of Oxygen Free Radicals on Excitation-Contraction Coupling in Ventricular Muscle. Circulation. 1996;94(10):2597–604.
23.
Grieve D. Oxidative stress in heart failure More than just damage. European Heart Journal. 2003;24(24):2161–3.
24.
Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, et al. Inhibitory Effects of Antioxidants on Neonatal Rat Cardiac Myocyte Hypertrophy Induced by Tumor Necrosis Factor-α and Angiotensin II. Circulation. 1998;98(8):794–9.
25.
Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drüeke T, Santangelo F, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney International. 2003;64(1):82–91.
26.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Annals of Internal Medicine. 1999;130(6):461–70.
27.
Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014;1(1):4–25.
28.
Ellman GL. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics. 1959;82(1):70–7.
29.
Góth L. A simple method for determination of serum catalase activity and revision of reference range. Clinica Chimica Acta. 1991;196(2–3):143–51.
30.
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International. 1996;49(5):1304–13.
31.
Feigenbaum H. Echocardiography. 1994;
32.
Lorell BH, Carabello BA. Left Ventricular Hypertrophy. Circulation. 2000;102(4):470–9.
33.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. The American Journal of Cardiology. 1986;57(6):450–8.
34.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2005;18(12):1440–63.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
